BHVN analyst estimates
Biohaven (BHVN) analyst ratings, the average price target and its range, and every firm's latest call.
BHVN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 22, 2026 | Robert W. Baird | Biohaven Pharma (BHVN) PT Raised to $48 at Baird | $48.00 |
| Sep 8, 2026 | RBC Capital | RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform | $19.00 |
| Aug 28, 2026 | Canaccord Genuity | Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN) | $21.00 |
| Aug 26, 2026 | Raymond James | Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James | $30.00 |
| Aug 12, 2026 | Morgan Stanley | Biohaven price target raised to $19 from $18 at Morgan Stanley | $19.00 |
| Jun 29, 2026 | Needham | BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform | $11.00 |
| May 13, 2026 | Morgan Stanley | Biohaven price target lowered to $18 from $21 at Morgan Stanley | $18.00 |
| Mar 4, 2026 | H.C. Wainwright | Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright | $10.00 |
| Mar 3, 2026 | Leerink Partners | Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates | $15.00 |
| Feb 5, 2026 | Goldman Sachs | Biohaven initiated with a Buy at Goldman Sachs | $23.00 |
| Jan 21, 2026 | RBC Capital | Biohaven upgraded to Outperform from Sector Perform at RBC Capital | $22.00 |
| Dec 3, 2025 | H.C. Wainwright | Biohaven downgraded to Neutral from Buy at H.C. Wainwright | $11.00 |
| Nov 26, 2025 | UBS | Biohaven downgraded to Neutral from Buy at UBS | $11.00 |
| Nov 18, 2025 | Morgan Stanley | Biohaven price target lowered to $26 from $54 at Morgan Stanley | $26.00 |
| Nov 5, 2025 | Robert W. Baird | Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird | $42.00 |
- 12 firms rate BHVN: 6 buy, 5 hold, 1 sell.
- The average price target is $24.67 from 6 analysts, from $11.00 to $48.00.
Updated 2026-11-03 00:46 UTC